BioLineRx Receives Notice Of Allowance For US Patent On BL-7010

(RTTNews) - BioLineRx Ltd. (BLRX) said Thursday that it has received a Notice of Allowance from the United States Patent and Trademark Office for a patent claiming the use of BL-7010, a novel polymer in preventing or decreasing gluten's deleterious effects on the gastrointestinal mucosa.

The patent, when issued, will be valid until at least 2026.

Additional patents claiming the BL-7010 composition and uses thereof are granted or pending in the US, Europe, Japan, Canada, Israel, India, China, Brazil, Russia, Australia, South Africa and Hong Kong, the company said.

BL-7010 is a novel, non-absorbable, orally available polymer intended for the treatment of celiac disease, a chronic, autoimmune, inflammatory disease of the small intestine characterized by damage to the lining of the small intestine and typically leads to dyspepsia, malabsorption and a variety of other symptoms.